Get the Stockscreener App
3.59
0.28%
0.010
Arbutus Biopharma Corp stock is traded at $3.59, with a volume of 903.44K.
It is up +0.28% in the last 24 hours and up +13.97% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$3.58
Open:
$3.6
24h Volume:
903.44K
Relative Volume:
1.22
Market Cap:
$688.20M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-8.1591
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+6.69%
1M Performance:
+13.97%
6M Performance:
+4.97%
1Y Performance:
-5.77%
1-Day Range:
$3.535
$3.66
1-Week Range:
$3.345
$3.66
52-Week Range:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.59 | 647.94M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Will Arbutus Biopharma Corporation bounce back from current support2025 Major Catalysts & Growth Focused Entry Reports - Newser
Applying chart zones and confluence areas to Arbutus Biopharma CorporationCEO Change & Long-Term Capital Growth Strategies - Newser
Multi asset correlation models including Arbutus Biopharma Corporation2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Published on: 2025-08-20 02:54:05 - Newser
Chart overlay techniques for tracking Arbutus Biopharma CorporationMarket Performance Report & Reliable Breakout Forecasts - Newser
Understanding Arbutus Biopharma Corporation’s price movementMarket Activity Summary & Low Risk High Win Rate Stock Picks - Newser
Sentiment analysis tools applied to Arbutus Biopharma CorporationMarket Trend Report & Stock Portfolio Risk Control - Newser
Technical analysis overview for Arbutus Biopharma Corporation stockWatch List & Stepwise Trade Signal Guides - Newser
Measuring Arbutus Biopharma Corporation’s beta against major indicesTrade Risk Report & Expert Approved Momentum Trade Ideas - Newser
Custom watchlist performance reports with Arbutus Biopharma CorporationPortfolio Value Summary & Low Drawdown Investment Ideas - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryJuly 2025 Update & High Accuracy Trade Alerts - Newser
Published on: 2025-08-19 03:41:21 - Newser
Published on: 2025-08-19 01:06:42 - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeQuarterly Performance Summary & Low Risk High Win Rate Picks - Newser
Real time scanner hits for Arbutus Biopharma Corporation explainedMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Volatility clustering patterns for Arbutus Biopharma CorporationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Can volume confirm reversal in Arbutus Biopharma CorporationMarket Performance Summary & Weekly Breakout Stock Alerts - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataJuly 2025 Earnings & High Win Rate Trade Alerts - Newser
Real time social sentiment graph for Arbutus Biopharma CorporationQuarterly Portfolio Report & Daily Volume Surge Signals - Newser
Exit strategy if you’re trapped in Arbutus Biopharma CorporationPortfolio Update Report & Stepwise Trade Signal Guides - Newser
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Chardan Capital Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Reports Q2 2025 Revenue of $10.7M and Appoints New Board Members - SSBCrack
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):